Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific

Jazz Pharmaceuticals has thrown its hat into the HER2 ring. For $50 million, the company has secured the chance to pay a further $325 million to take Zymeworks’ HER2-directed bispecific antibody forward after the release of pivotal data.